Renown Regional Medical Center

Summary

Renown Regional Medical Center is a medical facility located in Reno, Nevada. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Renown Regional Medical Center is involved with conducting 281 clinical trials across 501 conditions. There are 5 research doctors associated with this hospital, such as John A. Ellerton, Alan K. Ikeda, Lee Schwartzberg, MD, and Garrett Green, MD.

Top PIs

Clinical Trials running at Renown Regional Medical Center

Breast Cancer

Lung Cancer

Breast cancer

Pancreatic Cancer

Bladder Cancer

Esophageal cancer

Kidney Cancer

Cancer

Bladder Carcinoma

Testicular cancer

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.

Recruiting

2 awards

Phase 3

19 criteria

Sacituzumab Tirumotecan + Pembrolizumab

for Breast Cancer

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.

Recruiting

2 awards

Phase 3

3 criteria

PF-07220060 + Letrozole

for Breast Cancer

The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface); * locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastatic disease (the spread of cancer to other places in the body) * who have not received any prior systemic anti-cancer treatment for advanced/metastatic disease. Approximately half of the participants will receive PF-07220060 plus letrozole while the other half of participants will receive the investigator's choice of treatment plus letrozole. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.

Recruiting

2 awards

Phase 3

4 criteria